AtriCure price target raised to $66 from $61 at Canaccord

Canaccord raised the firm’s price target on AtriCure (ATRC) to $66 from $61 and keeps a Buy rating on the shares. The firm said they posted a solid Q4 and management raised the low-end of its adjusted EBITDA expectation by $2M due to a strong YE24.